INSP: CMS Coding Progress Will Gradually Support Future Reimbursement And Earnings Power

Analysts have cut the blended price target for Inspire Medical Systems from about $79 to about $52 as they factor in lower assumed revenue growth, more conservative profit margins, and ongoing reimbursement and coding uncertainty highlighted in recent Street research.

Analyst Commentary

Recent Street research on Inspire Medical Systems clusters around reimbursement mechanics, coding pathways for Inspire V, and how these issues flow through to growth expectations and valuation.

Across the board, analysts are updating models to reflect coding uncertainty, revised guidance, and a wide range of outcomes for reimbursement and physician billing. This is feeding directly into lowered price targets and several rating downgrades.

Bullish Takeaways

Some bullish analysts view the recent CMS update that mapped the Inspire V specific C code at parity with an existing hypoglossal nerve stimulation code as a positive sign for hospital reimbursement, which supports their long term revenue framework.
Confirmation that new HGNS C codes remain in the same APC as the prior code, with the hospital facility fee described as essentially unchanged at about US$31,500, removes a key downside risk in some bullish models and helps stabilize assumptions for procedure level economics.
Bullish analysts who maintain more constructive views acknowledge near term uncertainty, yet still model scenarios where management's long range revenue framework remains achievable, even after taking 2026 projections slightly below the low end of company guidance.
These supportive views tend to lean on the idea that reimbursement clarity is moving in a favorable direction, which, if sustained, could justify higher valuation multiples than those implied by the most cautious targets.

Bearish Takeaways

Bearish analysts focus on the lack of an official permanent code for Inspire V and view the timeline for such a code, described as potentially extending beyond January 1, 2028, as a major overhang on earnings visibility and stock performance.
Several bearish reports highlight concern that the company’s guidance assumes coding issues are already improving, while they see limited evidence of a sustainable improvement until there is a fully established and consistent coding pathway for centers.
New MAC billing changes and unresolved questions around physician fees and the impact of modifiers are cited as fresh headwinds that could weigh on procedure volumes, execution, and confidence in medium term growth forecasts.
Collectively, these concerns have led bearish analysts to lower price targets and shift ratings toward more cautious stances, reflecting higher perceived risk around the company’s ability to deliver against its longer term revenue ambitions under the current coding framework.

What's in the News

Inspire Medical Systems revised its full year 2026 revenue outlook to a range of US$825 million to US$875 million and guided to diluted EPS of US$0.07 to US$0.62. Source: Company earnings guidance update.
Stockholders approved an amendment to phase out the classified board structure. The company will move to annual election of all directors beginning with the 2029 annual meeting. Source: 2026 annual meeting of stockholders.
The company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Delaware on May 1, 2026. This filing made the board declassification changes effective upon submission. Source: Company corporate filing.
Prior to the annual meeting, Inspire Medical Systems had proposed this amendment to its Seventh Amended and Restated Certificate of Incorporation for stockholder approval at the April 30, 2026 AGM. Source: Company proxy materials.

Valuation Changes

Fair Value: Cut from about $79.42 to about $52.17, a reduction of roughly 34% in the modeled fair value estimate.
Discount Rate: Trimmed slightly from about 7.72% to about 7.59%, indicating a modest change in the required return used in the model.
Revenue Growth: Reduced from about 8.01% to about 2.56%, a large reset in the assumed long term revenue growth outlook.
Net Profit Margin: Brought down from about 8.48% to about 6.80%, reflecting more conservative expectations for future profitability.
Future P/E: Adjusted from about 26.47x to about 25.16x, a small compression in the valuation multiple applied to future earnings.

10 views

Key Takeaways

Transitory operational delays are expected to resolve soon, positioning the company for accelerated growth as new system adoption and reimbursement improvements unfold.
Market expansion and clinical enhancements will boost provider capacity and adoption, supporting sustained long-term revenue growth amid rising demand for sleep health solutions.
Execution delays, increased competition, operational missteps, and evolving market dynamics threaten revenue stability, margins, and long-term growth prospects for Inspire Medical Systems.

Catalysts

About Inspire Medical Systems

A medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The recent delay in transitioning centers to the Inspire V next-generation system-including slower onboarding, delayed SleepSync implementation, and the Medicare billing update-are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.
Expanded coverage and proposed reimbursement increases for Inspire's procedures (notably the expected 2026 Medicare OPPS rule enhancements and near-complete payer coverage of the new CPT code) will reduce patient out-of-pocket costs and incentivize additional adoption, supporting both revenue growth and longer-term earnings visibility.
The second half of 2025 will see a ramp in marketing and new center expansion following a purposeful pause in H1 amid the Inspire V launch; this resurgence in patient education, awareness campaigns, and provider capacity building should drive higher procedure volumes and top-line acceleration into 2026 and beyond.
Inspire V's clinical enhancements-shorter procedure times (20% reduction), elimination of the pressure-sensing lead, and workflow simplification-are already increasing implant throughput at transitioned centers (20%+ higher volumes), suggesting a meaningful lift in provider capacity and future revenue as the full installed base adopts these improvements.
Increasing prevalence of obstructive sleep apnea and rising global focus on sleep health are fueling ongoing expansion of Inspire's addressable market; as obesity rates and aging populations climb, structural demand tailwinds are likely to translate into sustained long-term procedure and revenue growth for the company.

Inspire Medical Systems Earnings and Revenue Growth

Inspire Medical Systems Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Inspire Medical Systems's revenue will grow by 2.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 14.3% today to 6.8% in 3 years time.
Analysts expect earnings to reach $67.1 million (and earnings per share of $2.18) by about June 2029, down from $131.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $47.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.8x on those 2029 earnings, up from 8.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.2x.
Analysts expect the number of shares outstanding to decline by 2.57% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.59%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The slower-than-expected rollout of Inspire V, driven by delays in center training, contracting, onboarding, and technical hurdles with implementing SleepSync, has materially reduced near-term revenue growth rates and deferred volume expansion, increasing execution risk and potentially causing a protracted recovery in revenue and margins into 2026.
Increased dependence on a single primary product (Inspire V) and the complexities of transitioning from Inspire IV introduce risks of technological obsolescence, operational missteps, or further customer delays, which could threaten stability of long-term revenue growth and earnings visibility if competitive alternatives emerge or adoption lags.
The need for higher patient marketing and territory expansion spend in the face of revenue pressure has driven operating expenses up faster than revenue growth, compressing net margins and earnings per share; this cost trend could persist if Inspire Medical Systems must continue elevated spend to regain growth momentum and offset competitive threats.
The potential for structural changes in sleep apnea therapy-such as increased use of GLP-1 drugs for weight loss (reducing OSA prevalence or changing patient eligibility) and broader adoption of non-invasive digital health solutions-could permanently shrink Inspire's addressable market or reduce demand for surgically implanted devices, thereby impacting long-term revenue growth and profitability.
Changes in reimbursement dynamics, especially regarding Medicare and shifting CPT codes, have created temporary barriers but also hint at a long-term risk: payer and regulatory pressure could limit coverage, reduce pricing power, or discourage high-volume implanters from treating certain patient groups-putting sustained pressure on both revenue and margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $52.17 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $65.0, and the most bearish reporting a price target of just $39.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $987.4 million, earnings will come to $67.1 million, and it would be trading on a PE ratio of 25.8x, assuming you use a discount rate of 7.6%.
Given the current share price of $40.58, the analyst price target of $52.17 is 22.2% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Inspire Medical Systems?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Sector Dislocations And Transitory Headwinds Will Create Long-Term Upside Opportunity